Business
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
(TheNewswire)   Toronto, Ontario – TheNewswire - 16 March, 2026 – Heli...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026\n(TheNewswire)\n\n\n\n \n\n\nToronto, Ontario – TheNewswire\n- 16 March, 2026 – Helix BioPharma Corp. (TSX:\n“HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)\n(“Helix” or the “Company”), a clinical-stage oncology\ncompany shaping a near future where today’s hard-to-treat cancers\nare vincible, today reported financial results and the filing of the\nCompany’s unaudited interim financial\nstatements as of and for the three- and\nsix-month periods ended January 31, 2026 (the\n“Financial\nStatements”), the management’s discussion\nand analysis (“MD&A”), and the certifications of the\nChief Executive Officer and Chief Financial Officer (respectively,\n“CEO” and “CFO”) relating to the Financial\nStatements (collectively, the “Interim Filings”). All values are in\nCanadian dollars unless stated otherwise. \n\n\n \n\n\n“While our current financial position reflects a\nchallenging capital markets environment for small-cap biotech\ncompanies, our focus remains firmly on securing the financing\nnecessary to advance Helix into its next phase,” said Thomas Mehrling, MD, PhD, Chief Executive\nOfficer of the Company. “The Management and\nBoard are actively pursuing financing opportunities aimed at securing\napproximately twelve months of operating runway, which will allow the\nCompany to pursue its near-term objectives, including listing on a\nU.S. securities exchange. While there is still work to be done, we\nhave reason to be cautiously optimistic as we intensify these efforts\nand expect to communicate further on our roadmap to achieve this goal\nsoon.” \n\n\n \n\n\nFinancial Highlights: \n\n\n \n\n\n\nThe Company incurred a net and total comprehensive loss\nfrom operations of $694,000 for the three months\nended January 31, 2026, and a loss of $1,702,000 for the six months\nended January 31, 2026, versus a net loss of $1,375,000 and $2,711,000\nfor the three and six months ended January 31, 2025, respectively. The\ndecrease in net loss was primarily due to the ...